Lipid-complexed camptothecin: Formulation and initial biodistribution and antitumor activity studies

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 531-538

  Sugarman, Steven M ^a,c   Zou, Yiyu ^a   Wasan, Kishor ^a,b   Poirot, Ken ^a   Kumi, Robert ^a   Reddy, Sara ^a   Perez Soler, Roman ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Lipid complexed camptothecin

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; LIPID COMPLEXED CAMPTOTHECIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG TISSUE LEVEL; GASTROINTESTINAL TRACT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; LEUKEMIA P 388; LUNG PARENCHYMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL SURVIVAL; HUMANS; LEUKEMIA L1210; LEUKEMIA P388; LIPIDS; METABOLIC CLEARANCE RATE; MICE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0029873920     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050425     Document Type: Article

References (23)

1. Wall ME, Wani MC, Cook CE, et al (1966) Plant anti-tumor agents. 1. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888
2. Gottlieb JA, Guarino AM, Call JB, et al (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461
3. Muggia FM, Creaven PJ, Hansen HH, et al (1972) Phase I clinical trial of weekly and daily treatment with camptotecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515
4. Moertel CG, Schutt RJ, Reitemeier RJ, et al (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
5. Hsiang YH, Hertzberg RP, Hecht S, et al (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873
6. Mattern M, Mong SM, Bartus HF, et al (1985) Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47: 1793
7. Hsiang YH, Liu LP (1988) Identificaion of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722
8. Tsao YP, D'Arpa P, Liu L (1992) The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of P34cdc2/cyclin B1. Cancer Res 32: 2720
9. Lock R, Ross W (1990) Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese Hamster ovary cells. Cancer Res 50: 3761
10. Hertzberg RP, Caranfa MJ, Holden KG, et al (1989) Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715
11. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077
12. Crow RT, Crothers DM (1992) Structural modifications of camptothecin and effects on topoisomerase I inhibition. J Med Chem 35: 4160
13. Giovanella BC, Hinz HR, Kozielski AJ, et al (1991) Complete growth inhibition of human cancer xenographs in nude mice by treatment with 20-(s)-camptothecin. Cancer Res 51: 3052
14. Slichenmyer WJ, Rowingsky EK, Donehower RC, et al (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271
15. Hart LG, Call JB, Oliverio VT (1969) A fluorometric method for determination of camptothecin in plasma and urine. Cancer Chemother Rep 53: 211
16. Fraley R, Subramani S, Berg P, et al (1980) Introduction of liposo me-encapsulated SV40 DNA into cells. J Biol Chem 255: 10431
17. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth cell kill. J Immunol Methods 119: 203
18. Loh JP, Ahmed AE (1990) Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr 530: 367
19. Kotting J, Berger MR, Unger C, et al (1992) Alkylphosphocholines: influence of structural variations on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol 30: 105
20. Kwon GS, Yokoyama M, Okano T, et al (1993) Biodistribution of micelle-forming polymer-drug conjugates. Pharm Res 10: 970
21. Burke TG, Staubus AE, Mishra AK, et al (1992) Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114: 8318
22. Burke TG, Zihou M (1993) Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32(20): 5352
23. Burke TG, Zihou M (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212(1): 285